LEADER 04268nam 2201273z- 450 001 9910557626103321 005 20240412204915.0 035 $a(CKB)5400000000045154 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/76735 035 $a(EXLCZ)995400000000045154 100 $a20202201d2021 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aBacterial Meningitis$eEpidemiology and Vaccination 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2021 215 $a1 electronic resource (274 p.) 311 $a3-0365-1807-X 311 $a3-0365-1808-8 330 $aThis timely collection of expert papers draws attention to the global burden of meningitis and the challenges faced by the WHO?s roadmap to defeat meningitis by 2030. The three main goals of the meningitis roadmap are to eliminate epidemics of bacterial meningitis, reduce cases and deaths from vaccine-preventable bacterial meningitis, and reduce disability and improve quality of life after meningitis of any cause. This book includes a wide range of original research and reviews on epidemiology and vaccination of bacterial meningitis that have direct relevance to advancing the goals of the roadmap. 517 $aBacterial Meningitis 606 $aResearch & information: general$2bicssc 606 $aBiology, life sciences$2bicssc 610 $ameningitis 610 $achild mortality 610 $aneonatal sepsis 610 $aglobal health 610 $aglobal health estimates 610 $amodelling 610 $aStreptococcus pneumoniae 610 $aHaemophilus influenzae 610 $aNeisseria meningitidis 610 $abacterial meningitis 610 $aS. pneumoniae 610 $aN. meningitidis 610 $aH. influenzae 610 $aS. agalactiae 610 $aconjugate vaccines 610 $apost-vaccine surveillance 610 $avaccine 610 $aAfrica 610 $amathematical modelling 610 $asusceptibility 610 $ainvasive bacterial infections 610 $acomplement 610 $agenetic factors 610 $aStreptococcus agalactiae 610 $agroup B streptococci 610 $acapsule 610 $ameningococcal group 610 $anongroupable 610 $ameningococcal carriage 610 $ainvasive meningococcal disease 610 $ameningococcal urethritis 610 $aneonatal infections 610 $aepidemiology 610 $aantibiotic resistance 610 $aetiologic diagnosis 610 $aenterovirus 610 $agroup B Streptococcus 610 $aneurological sequelae 610 $ahearing loss 610 $aseizure 610 $aepilepsy 610 $ahydrocephalus 610 $afocal neurological deficit 610 $acorticosteroid 610 $adexamethasone 610 $ainvasive pneumococcal disease 610 $apneumococcal conjugate vaccines 610 $aserotypes 610 $avaccine impact 610 $apneumococcal meningitis 610 $aserotype distribution 610 $aPCV impact 610 $aglobal 610 $ameta-analysis 610 $asurveillance 610 $ameningococcus 610 $apneumococcus 610 $aHib 610 $agroup B streptococcus 610 $aconjugate vaccine 610 $arapid diagnostic test 610 $anational reference laboratory 610 $acerebrospinal fluid 610 $aNiger 610 $aBurkina Faso 610 $atuberculosis 610 $atuberculous meningitis 610 $aTBM 610 $achildren 610 $aimpact of Hib conjugate vaccine 610 $aHia 610 $aNTHi 610 $aburden 610 $asocial and economic costs 610 $aWHO meningitis roadmap 610 $adisability 615 7$aResearch & information: general 615 7$aBiology, life sciences 700 $aStuart$b James M$4edt$01309771 702 $aStuart$b James M$4oth 906 $aBOOK 912 $a9910557626103321 996 $aBacterial Meningitis$93029586 997 $aUNINA